KLBF – To focus on oncology drug innovation and penetration in ASEAN next year

KLBF – To focus on oncology drug innovation and penetration in ASEAN next year Kalbe Farma (KLBF) plans to expand its penetration into the oncology drug market in ASEAN while also supporting the National Health Insurance program by 2025. For its consumer product segment, KLBF aims to develop preventive and wellness product categories. Additionally, the nutrition segment will focus on launching ready-to-drink products at more affordable prices, and the distribution segment will expand its medical device offerings. Note that, KLBF is targeting net profit growth of 13–15% yoy in 2024. KLBF has already recorded revenue of IDR 24.23 tn (+7.4% yoy) and net profit of IDR 2.37 tn (+15.2% yoy) in 9M24. (Source : Bisnis Indonesia)